Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Current guidelines for follow-up of high-risk adenomas may not apply to all patients

05 Oct 2019

A recent study suggests that the 2012 Multi-Society Task Force recommendation for the surveillance of high-risk adenoma (HRA) may not be applicable to all patients.

Patients who were followed at a median of 4.5 years did not appear to have more HRA than those who were followed at 3 years (25.2 percent vs 21.0 percent; p=0.062). Baseline characteristics were comparable between the two groups.

The following factors were predictors of future HRAs: older age, male gender, having a history of polyps and piecemeal resection of an HRA. The removal of ≥3 adenomas in 2008 as well as a combination of multiple, large and advanced polyps were associated with a higher risk of future HRAs.

“We showed that a combination of patient demographics, procedural factors and pathology best determines the surveillance colonoscopy interval,” the authors said.

This study sought to determine whether variation from the 3-year follow-up interval correlated with subsequent HRA. A total of 495 patients who had their HRA removed during a 2008 colonoscopy were analysed in 2016. The frequency of finding another HRA at follow-up intervals were then compared.

The current guidelines were used as the referent group. Logistical regression was performed to determine whether any patient characteristics, procedural factors or HRA type predicted the development of HRAs on follow-up colonoscopy.

HRAs included an adenoma measuring ≥10 mm, ≥3 adenomas found during a single procedure, and an adenoma with high-grade dysplasia or villous architecture. The current Multi-Society Task Force guideline for timing of surveillance colonoscopy after removal of an HRA is 3 years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.